An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer, according to scientists from the German Cancer Research Center (DKFZ) in Heidelberg. They have reported their findings in Nature. The researchers have discovered a surprising link between energy metabolism and...
Tag: <span>Acute myeloid leukemia (AML)</span>
Post
Idhifa approved for some with acute myeloid leukemia
(HealthDay)—Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML). The mutation in the IDH2 gene can be diagnosed with a newly approved companion diagnostic, the RealTime IDH2 Assay, the agency said in a news...
Post
Immunotherapy strategy could be beneficial for relapsed acute myeloid leukemia
ATLANTA – University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed. Seven out of 18 patients with relapsed or persistent AML, or nearly 39 percent, had a...
Post
Researchers Find “Executioner Protein” That Causes Cancer Cells to Self-Destruct Without Hurting Healthy Cells
IN BRIEF Scientists have discovered a way to use the “executioner protein” BAX to induce apoptosis in cancer cells while leaving healthy cells intact. The treatment has so far been applied only to acute myeloid leukemia (AML) cells but may have broader uses. KILLING CANCER WITH APOPTOSIS Albert Einstein College of Medicine scientists have induced...
Post
Chemo-boosting drug discovered for leukemia
Drugs developed to treat heart and blood vessel problems could be used in combination with chemotherapy to treat an aggressive form of adult leukemia, new research led by the Francis Crick Institute reveals. In a study published in Cancer Cell, researchers at the Francis Crick Institute, King’s College London and Barts Cancer Institute discovered that acute myeloid...
Post
New treatment approved for acute myeloid leukemia
(HealthDay)—The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia (AML). AML is an aggressive blood cancer that forms in the bone marrow. “Vyxeos combines two commonly used chemotherapies into a single formulation that may help...
Post
Stem-cell researchers solve mystery of relapse in acute myeloid leukemia
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins. They have also identified two distinct stem-cell like populations from which relapse can arise in different patients in this aggressive cancer...
Post
New antibody uses 1-2 punch to potentially treat blood cancers
Antibody PF-06747143 both attacks AML tumor cells and moves them from the nurturing bone marrow environment into the peripheral blood streams, where they are more vulnerable. Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood...
Post
New leukemia treatment outperforms standard chemotherapies
Researchers at ANU are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies. Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukemia (AML) in mice using the new treatment. “Not only have we been able...